Welcome to our dedicated page for Cardlytics SEC filings (Ticker: CDLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Cardlytics, Inc. (NASDAQ: CDLX) SEC filings, including current reports on Form 8-K and other regulatory documents filed with the U.S. Securities and Exchange Commission. Cardlytics operates as a commerce media platform in the advertising services sector, and its filings offer detailed insight into financial performance, governance, and material corporate events.
Recent Form 8-K filings from Cardlytics document a range of topics. Some filings furnish earnings press releases that present quarterly results, including GAAP and non-GAAP measures such as Billings, Adjusted Contribution, Adjusted EBITDA, Adjusted Net Loss, and Free Cash Flow. These filings also describe key operating metrics like monthly qualified users (MQUs) and adjusted contribution per user (ACPU), along with management’s discussion of trends and performance.
Other 8-K filings report material corporate actions such as workforce reduction plans under cost-reduction initiatives, amendments to significant agreements with partners, and changes to executive compensation and severance arrangements. Cardlytics has also filed 8-Ks describing the appointment of a Chief Financial Officer and related equity awards and severance protections, providing detail on compensation terms and vesting conditions.
Through these filings, investors can review how Cardlytics manages its capital structure, including disclosures about convertible senior notes, credit facilities, and repayment of debt. The company’s filings also confirm that its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on The Nasdaq Stock Market LLC under the symbol CDLX.
On Stock Titan, users can access Cardlytics’ SEC filings as they are made available from EDGAR, along with AI-powered summaries that help explain the content and implications of complex documents. These tools can assist in understanding Cardlytics’ earnings reports, non-GAAP metrics, insider and executive-related disclosures, and other regulatory information without reading every line of each filing.
CDLX Form 144 lists a proposed resale of 40,296 shares of Common Stock tied to Restricted Stock Vesting dated 03/31/2026. The filing also shows a prior sale of 6,253 shares by Nicholas H. Lynton on 01/05/2026 and references 55,054,268 in a column dated 04/01/2026.
CDLX notified a Rule 144 notice for proposed resale of 62,549 shares of Common Stock. The filing lists the securities as resulting from Restricted Stock Vesting dated 03/31/2026 and classifies the transaction as compensation. The excerpt also reports prior dispositions by Amit Gupta totaling 102,015 shares across three trades in January–February 2026 with dollar proceeds shown per trade.
Cardlytics, Inc. is soliciting proxies for its Annual Meeting on May 20, 2026 to elect three Class II directors, ratify Deloitte & Touche LLP as auditors, seek stockholder approval for a board‑determined reverse stock split at a ratio of 1:5 to 1:15 (with corresponding authorized shares reduction), and hold an advisory vote on named executive officer compensation. The record date is March 25, 2026 and there were 55,070,709 shares outstanding on that date. Proxy materials and voting instructions will be furnished primarily via the Internet.
CDLX — Notice of proposed resale of 50,000 shares of Common Stock. The filing lists 50,000 common shares tied to a Restricted Stock Vesting event dated 08/14/2024 with the issuer shown as the source and the transaction labeled Compensation.
The form records a recent sale of 8,607 shares on 01/05/2026 for $10,072.77. The filing identifies a brokerage account at Fidelity Brokerage Services and shows a filing date of 03/25/2026 on NASDAQ-listed securities.
Cardlytics, Inc. has completed the sale of its Bridg platform business to PAR Technology Corporation, transferring assets and rights primarily related to Bridg to PAR’s subsidiary DB Sub, LLC. As consideration, Cardlytics received 1,810,222 shares of PAR common stock, reflected as $25.4 million of stock in the pro forma adjustments.
Bridg is now treated as a discontinued operation, and Cardlytics has filed unaudited pro forma condensed consolidated financial statements for 2023–2025. On a pro forma basis for 2025, revenue from continuing operations is $212.3 million versus historical $233.3 million, and the net loss from continuing operations narrows to $91.5 million from $103.5 million. For 2024, the pro forma net loss from continuing operations is $40.4 million, compared with a historical net loss of $189.3 million, largely due to removing Bridg-related impairment charges.
The company estimates a $13.9 million gain on the transaction, based on the stock consideration, expected transaction costs of about $1.6 million, and Bridg net assets of approximately $9.9 million as of December 31, 2025. Management emphasizes that these pro forma figures and the gain estimate are preliminary and provided for illustrative purposes only.
Cardlytics, Inc. reports 2025 results showing revenue of $233.3 million, down 16.2% from $278.3 million in 2024, and billings of $385.0 million, down 13.3%. Net loss narrowed to $103.5 million from $189.3 million, and accumulated deficit reached $1.4 billion.
The company remains heavily dependent on its Cardlytics commerce media platform and a small group of large financial institution partners such as Chase and Wells Fargo. Its relationship with Bank of America, one of its top three partners, ended in February 2026 after a non‑renewal notice in 2025.
Cardlytics has agreed to sell substantially all assets of its Bridg data platform to an affiliate of PAR Technology, subject to closing conditions, which would leave future revenue and billings solely tied to the Cardlytics platform. Management highlights macroeconomic risks, rising tariffs, competitive pressures and cybersecurity threats, while emphasizing its large-scale purchase data, proprietary analytics and network effects as key competitive strengths.
Cardlytics reported fourth-quarter and full-year 2025 results showing sharp top-line pressure but better profitability and cash flow. Q4 revenue was $56.1 million, down 24.2% year over year, while full-year revenue was $233.3 million, down 16.2%. Q4 net loss narrowed to $8.3 million from $15.6 million, and full-year net loss improved to $103.5 million from $189.3 million. Non-GAAP metrics strengthened: Q4 adjusted EBITDA rose to $8.5 million and full-year adjusted EBITDA to $10.1 million, with free cash flow improving to $10.5 million in Q4 and to a smaller full-year outflow of $6.5 million. MQUs grew to 227.0 million in Q4 and 224.2 million for 2025, but ACPU declined to $0.12 in Q4 and $0.50 for the year. Guidance for Q1 2026 signals significant year-over-year declines in Billings, revenue and adjusted contribution, with adjusted EBITDA expected to be negative.
Gupta Amit reported acquisition or exercise transactions in this Form 4 filing.
Cardlytics, Inc. Chief Executive Officer Amit Gupta received an equity grant of 1,500,000 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Cardlytics common stock at no purchase price.
The RSU award will vest in equal amounts quarterly over a two-year period through April 1, 2028, as long as Gupta remains employed by Cardlytics on each vesting date. This award increases his directly held RSUs to 1,500,000, further tying his compensation to the company’s future share performance.
Cardlytics, Inc. reported that Chief Legal & Privacy Officer Lynton Nicholas Hollmeyer acquired 220,000 restricted stock units (RSUs) as an equity award. Each RSU represents a right to receive one share of common stock. The award vests in equal quarterly installments over two years through April 1, 2028, contingent on his continued employment with the company.
Cardlytics, Inc. Chief Executive Officer Amit Gupta reported a combination of stock vesting and related share sales. On February 16, 2026, he acquired 250,000 shares of common stock through the exercise/settlement of restricted stock units (RSUs), each RSU representing the right to receive one share or its cash equivalent.
According to the filing, Gupta then sold a total of 97,208 common shares on February 17–18, 2026 in open-market transactions at weighted average prices of $0.902 and $0.926 per share. A footnote states these sales were made solely to satisfy tax withholding obligations arising from the RSU share delivery and not for any other purpose. After these transactions, Gupta directly owned 659,644 common shares.
The RSU awards referenced cover 500,000 shares each, granted on August 21, 2024 and January 29, 2025, and vest in four 25% installments over 24 months following August 16, 2024, conditioned on continued employment.